Bristol-Myers Squibb seen as solid but no longer a clear buy due to slow growth and revenue decline risks

Bristol-Myers Squibb remains a solid investment with an attractive dividend yield of 4.3%, supported by free cash flow. However, its growth prospects have dimmed, with analysts expecting overall revenue to decline despite the growth portfolio now surpassing the legacy one. Debt levels have been reduced but still require monitoring if revenue continues to fall. The stock's valuation is appealing on free cash flow, but wide variations in intrinsic value based on growth assumptions make it a hold rather than a strong buy at this time.